Rapamycin and CCI-779;La rapamycine et le CCI-779

Bulletin du Cancer

Volumn 86, Issue 10, 1999, Pages 808-811

  Alexandre, Jérôme ^a   Raymond, Éric ^a   Armand, Jean Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

CCI 779; mTOR; Rapamycin

Indexed keywords

ANTINEOPLASTIC AGENT; CCL 779; CYCLOSPORIN; MACROLIDE; MESSENGER RNA; PHOSPHOTRANSFERASE; RAPAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PROTEIN KINASE INHIBITOR; TEMSIROLIMUS;

ANTINEOPLASTIC ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; HYPERLIPIDEMIA; REVIEW; RNA TRANSLATION; THROMBOCYTOPENIA; TUMOR CELL; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; DISEASE MODEL; DRUG EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PROTEIN SYNTHESIS; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS, PHASE I; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MICE; NEOPLASM TRANSPLANTATION; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; SIROLIMUS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032589825     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. 1. Vezina C. Antimicrobial activity of streptomyces and fungi isolated from rapa Nui soil samples. 5th annual meeting of the Canadian Society of Chemotherapy, Toronto, April 16, 1969.
2. 2. Kahan BD. Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients. Transplant Proc 1998; 30: 2185-8.
3. 3. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive molecules. Transplant Rev 1992; 6: 39-87.
4. 4. Thomas G, Hall MN. TOR signalling and control of cell growth. Curr Op Cell Biol 1997; 9: 782-7.
5. 5. Sausville EA. New agents-noncytotoxics, antiangiogenesis. ASCO Educational Book 1998; 112-7.
6. 6. Albers MW, Williams RT, Brown EJ, Tanaka A, Hall FL, Schreiber SL. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-cdk association in early G1 of an osteosarcoma cell line. J Biol Chem 1993; 268: 22825-9.
7. 7. Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 1994; 54: 903-7.
8. 8. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70S6K phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996; 56: 3895-7.
9. 9. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992; 257: 973-7.
10. 10. Magge KP, Pryor AD, Marks JR, Iglehart JD, Miron A. Rapamycin (sirolimus) blocks estrogen mediated growth of breast cancer cell lines. Proc Am Ass Cancer Res 1999; 40: 636 (abstr. 4197).
11. 11. Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-dependent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999; 59: 886-94.
12. 12. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995; 55: 1982-8.
13. 13. Sabers CJ, Martin MM, Brunn GJ. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270: 815-22.
14. 14. Beretta L, Grolleau A. La rapamycine: identification d'une nouvelle voie de signalisation des facteurs de croissance, réglant le débur de la traduction. Médecine/sciences 1998; 14: 600-2.
15. 56K. J Biol Chem 1998; 273: 4776-82.
16. 16. Hashemolhosseini S, Nagamine Y, Morley SJ, Destivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998; 273: 14424-9.
17. kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372: 570-3.
18. 18. Veverka KA, Germain GS, Dilling MB, Houghton PJ. Overexpression of bcl2 fails to protect rhabdomyosarcoma cells from rapamycin-induced apoptosis. Proc Am Ass Cancer Res 1998; 39: 571 (abstr. 3880).
19. 19. Dilling MB, Hosoi H, Liu LN, Germain GS, Houghton PJ. Intrinsic resistance to rapamycin in human tumor cells may correlate with c-myc protein levels. Proc Am Ass Cancer Res 1999; 40: 428 (abstr. 2827).
20. 20. Beamish H, Williams R, Chen P, Khanna KK, Hobson K, Watters D. Rapamycin resistance in ataxia-relangiectasia. Oncogene 1996; 13: 963-70.
21. 21. Trepanier DJ, Gallant H, Legatt DF, Yatscoff RW. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem 1998; 31: 345-51.
22. 22. Beretta L, Svitkin YV, Sonenberg N. Rapamycin stimulates vital protein synthesis and augments the shuroff of host protein synthesis upon picornavirus infection. J Virol 1996; 70: 8993-6.
23. 23. Gibbons JJ, Discafani C, Peterson R, Hernandez R, Skotnicki J, Frost P. The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo. Proc Am Ass Cancer Res 1999; 40: 301 (abstr. 2000).
24. 24. Geoerger B, Kerr K, Janss AJ, Sutton LN, Phillips PC. Rapamycin analog CCI-779 inhibits growth of human medulloblastoma xenografts. Proc Am Ass Cancer Res 1999; 40: 603 (abstr. 3978).